Molecular Subtypes and Biomarkers of Advanced Cutaneous T-Cell Lymphoma

Overview

This study identifies three molecular subtypes of advanced cutaneous T-cell lymphoma (CTCL) with distinct clinical phenotypes. Specific biomarkers were identified that may correlate with treatment response and disease progression.

Background

Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas, with mycosis fungoides and Sézary syndrome being the most prevalent subtypes. Advanced-stage CTCL is aggressive and presents significant challenges in treatment due to interpatient variability in response and prognosis. Understanding the molecular characteristics of these subtypes is crucial for improving therapeutic strategies.

Data Highlights

Key Findings

• Three molecular subtypes of advanced CTCL were identified: intracellular signaling, metabolic, and extracellular matrix remodeling.
• The PI3K-AKT-mTOR pathway was notably upregulated in the intracellular signaling subtype.
• Phospho-AKT expression levels correlated with treatment response to PI3Kδ inhibitors.
• Potential biomarkers for treatment responsiveness include CTSB, GSTO1, and WDFY4.
• GOLGA1 and STIP1 may serve as biomarkers for predicting disease progression.

Clinical Implications

The identification of molecular subtypes and associated biomarkers may provide insights for clinicians managing patients with advanced-stage CTCL.

Conclusion

This study provides a framework for understanding the molecular diversity of advanced CTCL. Validation of these findings in larger studies is essential.

Related Resources & Content

1. Blood Cancer Journal, 2020 -- Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features
2. Frontiers in Hematology, 2026 -- Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas
3. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023 - PubMed
4. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data
5. Blood Cancer Journal — Molecular Classification of Acute Myeloid Leukemia: Integrative Subtype Analysis
6. Blood Cancer Journal — Macrophages Expressing PDL1 Infiltrate Diffuse Large B-Cell Lymphoma and Enhance Tumor Growth in a MYC-Driven Experimental Model
7. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023 - PubMed
8. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data - ScienceDirect
9. Full article: Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab